Literature DB >> 29279100

Long-term toxicity of the treatment for germ cell-cancer. A review.

P Maroto1, G Anguera2, C Martin2.   

Abstract

Testicular germ-cell cancer (GCC) is a curable disease. Stage I patients are mostly cured by surgery alone. For those with good prognosis advanced disease, radiotherapy in some patients with stage II Seminoma and chemotherapy for all other patients, are responsible for 95% of long-term survivors. Unfortunately, despite this high level of curability, overall survival has been reported lower for those patients receiving either radiotherapy or chemotherapy versus patients treated by surgery alone. Long-term survivors face a higher incidence of second neoplasms, and a higher risk of cardiovascular disease and metabolic syndrome than expected. Other non-life-threatening toxicities such as ototoxicity, neurotoxicity and fertility problems are common. This paper reviews the potential causes of the higher mortality among long-term survivors of testicular tumors, the incidence of them and some recommendations for the diagnoses and prevention of long-term sequelae in patients with GCC.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Germ-cell cancer; Toxicity

Mesh:

Year:  2017        PMID: 29279100     DOI: 10.1016/j.critrevonc.2017.11.015

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  5 in total

1.  Clinical characteristics of testicular seminoma in individuals in West China: a 10-year follow-up study.

Authors:  Zeyu Chen; Shi Qiu; Dehong Cao; Jianbing Guo; Bo Chen; Yin Huang; Li Lai; Yige Bao; Qiang Dong; Liangren Liu; Qiang Wei
Journal:  Cancer Manag Res       Date:  2019-08-14       Impact factor: 3.989

2.  Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953-2015: A population-based prospective cohort study.

Authors:  Øivind Kvammen; Tor Åge Myklebust; Arne Solberg; Bjørn Møller; Olbjørn Harald Klepp; Sophie Dorothea Fosså; Torgrim Tandstad
Journal:  PLoS One       Date:  2019-12-18       Impact factor: 3.240

3.  Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study.

Authors:  Klaus-Peter Dieckmann; Tomas Pokrivcak; Lajos Geczi; David Niehaus; Inken Dralle-Filiz; Cord Matthies; Tamas Dienes; Stefanie Zschäbitz; Pia Paffenholz; Tanja Gschliesser; Renate Pichler; Michal Mego; Pia Bader; Friedemann Zengerling; Julia Heinzelbecker; Philipp Krausewitz; Susanne Krege; Gaetano Aurilio; Cem Aksoy; Marcus Hentrich; Christoph Seidel; Péter Törzsök; Tim Nestler; Matthaeus Majewski; Andreas Hiester; Tomas Buchler; Sonia Vallet; Hana Studentova; Sandra Schönburg; Dora Niedersüß-Beke; Julia Ring; Emanuela Trenti; Axel Heidenreich; Christian Wülfing; Hendrik Isbarn; Uwe Pichlmeier; Martin Pichler
Journal:  Ther Adv Med Oncol       Date:  2022-03-31       Impact factor: 8.168

Review 4.  Early-Onset Cancers in Adults: A Review of Epidemiology, Supportive Care Needs and Future Research Priorities.

Authors:  Ashleigh C Hamilton; David W Donnelly; Deirdre Fitzpatrick; Helen G Coleman
Journal:  Cancers (Basel)       Date:  2022-08-20       Impact factor: 6.575

5.  Is there still a place for retroperitoneal lymph node dissection in clinical stage 1 nonseminomatous testicular germ-cell tumours? A retrospective clinical study.

Authors:  K-P Dieckmann; P Anheuser; M Kulejewski; R Gehrckens; B Feyerabend
Journal:  BMC Urol       Date:  2018-10-26       Impact factor: 2.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.